HEPION PHARMACEUTICALS, INC. (HEPA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
19/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinHEPA / S&P 19.30% / 15.20% |
LoseHEPA / S&P HEPA unavailable / 15.00% |
LoseHEPA / S&P -99.59% / 50.40% |
| 2026-Q10/3 |
LoseHEPA / S&P -5.00% / -4.33% |
LoseHEPA / S&P HEPA unavailable / 11.30% |
LoseHEPA / S&P -99.75% / 27.70% |
| 2025-Q41/3 |
WinHEPA / S&P 20.00% / 2.65% |
LoseHEPA / S&P HEPA unavailable / 9.00% |
LoseHEPA / S&P -97.86% / 13.40% |
| 2025-Q30/3 |
LoseHEPA / S&P -37.50% / 8.12% |
LoseHEPA / S&P HEPA unavailable / 4.61% |
LoseHEPA / S&P -98.52% / 13.45% |
| 2025-Q20/3 |
LoseHEPA / S&P -81.40% / 10.94% |
LoseHEPA / S&P HEPA unavailable / 4.83% |
LoseHEPA / S&P -93.05% / 10.63% |
| 2025-Q10/3 |
LoseHEPA / S&P -98.17% / -4.27% |
LoseHEPA / S&P HEPA unavailable / 4.98% |
LoseHEPA / S&P -87.43% / 10.57% |
| 2024-Q40/3 |
LoseHEPA / S&P -29.85% / 2.41% |
LoseHEPA / S&P HEPA unavailable / 5.25% |
LoseHEPA / S&P -82.71% / 6.15% |
| 2024-Q31/3 |
LoseHEPA / S&P -34.31% / 5.89% |
LoseHEPA / S&P HEPA unavailable / 5.89% |
WinHEPA / S&P 5527.08% / 6.11% |
| 2024-Q21/3 |
LoseHEPA / S&P -59.04% / 4.28% |
LoseHEPA / S&P HEPA unavailable / 5.38% |
WinHEPA / S&P 5482.70% / 5.12% |
| 2024-Q11/3 |
LoseHEPA / S&P -23.15% / 10.56% |
LoseHEPA / S&P HEPA unavailable / 5.71% |
WinHEPA / S&P 4625.07% / 5.59% |
| 2023-Q41/3 |
LoseHEPA / S&P -35.07% / 11.69% |
LoseHEPA / S&P HEPA unavailable / 6.81% |
WinHEPA / S&P 5077.06% / 7.78% |
| 2023-Q31/3 |
LoseHEPA / S&P -52.48% / -3.27% |
LoseHEPA / S&P HEPA unavailable / 7.52% |
WinHEPA / S&P 33.05% / -5.03% |
| 2023-Q21/3 |
LoseHEPA / S&P -32.43% / 8.74% |
LoseHEPA / S&P HEPA unavailable / 9.50% |
WinHEPA / S&P 64.88% / -8.57% |
| 2023-Q12/3 |
WinHEPA / S&P 159.00% / 7.50% |
LoseHEPA / S&P HEPA unavailable / 10.77% |
WinHEPA / S&P 524.88% / -15.69% |
| 2022-Q41/3 |
LoseHEPA / S&P -40.59% / 7.56% |
LoseHEPA / S&P HEPA unavailable / 11.88% |
WinHEPA / S&P 2431.91% / -17.99% |
| 2022-Q31/3 |
LoseHEPA / S&P -11.87% / -4.88% |
LoseHEPA / S&P HEPA unavailable / 13.47% |
WinHEPA / S&P 2751.52% / -1.41% |
| 2022-Q21/3 |
LoseHEPA / S&P -55.58% / -16.10% |
LoseHEPA / S&P HEPA unavailable / 13.71% |
WinHEPA / S&P 710.00% / 11.04% |
| 2022-Q12/3 |
WinHEPA / S&P 13.16% / -4.60% |
LoseHEPA / S&P HEPA unavailable / 15.97% |
WinHEPA / S&P 57.25% / 42.23% |
| 2021-Q40/3 |
LoseHEPA / S&P -25.49% / 11.03% |
LoseHEPA / S&P HEPA unavailable / 15.00% |
LoseHEPA / S&P -78.92% / 96.40% |
| 2021-Q30/3 |
LoseHEPA / S&P -22.73% / 0.58% |
LoseHEPA / S&P HEPA unavailable / 10.77% |
LoseHEPA / S&P HEPA unavailable / 69.42% |
| 2021-Q20/3 |
LoseHEPA / S&P 7.61% / 8.55% |
LoseHEPA / S&P HEPA unavailable / 6.58% |
LoseHEPA / S&P HEPA unavailable / 51.81% |
| 2021-Q10/3 |
LoseHEPA / S&P -15.98% / 6.17% |
LoseHEPA / S&P HEPA unavailable / -1.06% |
LoseHEPA / S&P HEPA unavailable / 7.39% |
| 2020-Q40/3 |
LoseHEPA / S&P -29.58% / 12.15% |
LoseHEPA / S&P HEPA unavailable / -3.72% |
LoseHEPA / S&P HEPA unavailable / -33.42% |
| 2020-Q30/3 |
LoseHEPA / S&P 8.74% / 8.93% |
LoseHEPA / S&P HEPA unavailable / -2.04% |
LoseHEPA / S&P HEPA unavailable / -27.10% |
| 2020-Q21/3 |
WinHEPA / S&P 61.58% / 20.54% |
LoseHEPA / S&P HEPA unavailable / -0.46% |
LoseHEPA / S&P HEPA unavailable / -27.11% |
| 2020-Q10/3 |
LoseHEPA / S&P -66.98% / -19.60% |
LoseHEPA / S&P HEPA unavailable / 3.47% |
LoseHEPA / S&P HEPA unavailable / -14.75% |
| 2019-Q41/3 |
WinHEPA / S&P 121.49% / 9.07% |
LoseHEPA / S&P HEPA unavailable / 5.36% |
LoseHEPA / S&P HEPA unavailable / 2.99% |
| 2019-Q30/3 |
LoseHEPA / S&P -41.97% / 1.70% |
LoseHEPA / S&P HEPA unavailable / 5.02% |
LoseHEPA / S&P HEPA unavailable / 0.21% |
| 2019-Q20/3 |
LoseHEPA / S&P -73.52% / 4.30% |
LoseHEPA / S&P HEPA unavailable / 6.64% |
LoseHEPA / S&P HEPA unavailable / 8.65% |
| 2019-Q10/3 |
LoseHEPA / S&P -20.21% / 13.65% |
LoseHEPA / S&P HEPA unavailable / 8.12% |
LoseHEPA / S&P HEPA unavailable / 14.29% |
| 2018-Q40/3 |
LoseHEPA / S&P -49.73% / -13.52% |
LoseHEPA / S&P HEPA unavailable / 9.05% |
LoseHEPA / S&P HEPA unavailable / 18.23% |
| 2018-Q30/3 |
LoseHEPA / S&P -56.85% / 7.71% |
LoseHEPA / S&P HEPA unavailable / 10.21% |
LoseHEPA / S&P HEPA unavailable / 19.06% |
| 2018-Q20/3 |
LoseHEPA / S&P -30.85% / 3.43% |
LoseHEPA / S&P HEPA unavailable / 9.03% |
LoseHEPA / S&P HEPA unavailable / 14.46% |
| 2018-Q10/3 |
LoseHEPA / S&P -34.72% / -0.76% |
LoseHEPA / S&P HEPA unavailable / 7.68% |
LoseHEPA / S&P HEPA unavailable / 12.46% |
| 2017-Q40/3 |
LoseHEPA / S&P -30.77% / 6.64% |
LoseHEPA / S&P HEPA unavailable / 7.03% |
LoseHEPA / S&P HEPA unavailable / 13.82% |
| 2017-Q30/3 |
LoseHEPA / S&P -10.34% / 4.48% |
LoseHEPA / S&P HEPA unavailable / 5.68% |
LoseHEPA / S&P HEPA unavailable / 17.57% |
| 2017-Q20/3 |
LoseHEPA / S&P -67.23% / 3.09% |
LoseHEPA / S&P HEPA unavailable / 4.83% |
LoseHEPA / S&P HEPA unavailable / 17.74% |
| 2017-Q11/3 |
WinHEPA / S&P 47.50% / 6.07% |
LoseHEPA / S&P HEPA unavailable / 3.67% |
LoseHEPA / S&P HEPA unavailable / 13.32% |
| 2016-Q41/3 |
WinHEPA / S&P 12.15% / 3.82% |
LoseHEPA / S&P HEPA unavailable / 2.09% |
LoseHEPA / S&P HEPA unavailable / 7.05% |
| 2016-Q30/3 |
LoseHEPA / S&P 2.88% / 3.85% |
LoseHEPA / S&P HEPA unavailable / 0.20% |
LoseHEPA / S&P HEPA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | HEPA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -20.90% | 20.78% |
| Annualized return | -20.90% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | HEPA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -87.37% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | HEPA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -80.45% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |